ImmuneSensor is developing small molecule cGAS inhibitors as a potential treatment for diseases and conditions caused by aberrant activation of the cGAS-STING pathway including:
MONOGENIC AUTOINFLAMMATORY SYNDROMES
Aicardi-Goutieres syndrome (AGS)
COPA syndrome
AUTOIMMUNE DISEASES
Systemic lupus erythematosus
Rheumatoid arthritis
NEUROLOGICAL DISORDERS
Alzheimer’s disease
Parkinson’s disease
Huntington’s disease
Amyotrophic lateral sclerosis and frontotemporal dementia (FTD)
Charcot Marie Tooth syndrome
Age-dependent macular degeneration
METABOLIC DISEASES
Nonalcoholic steatohepatitis
Acute pancreatitis
Kidney Diseases
ImmuneSensor expects to advance its potential best-in-class orally available small molecule cGAS inhibitor known as IMSB301 to human clinical trials in 2024. In preclinical models, IMSB301 rescued development of mortal inflammatory diseases in genetically engineered mouse models in which the cGAS-STING pathway is chronically activated. In addition, IMSB301 was shown to provide significant therapeutic benefit in mouse models of inflammatory arthritis.